PT669986E - Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem - Google Patents

Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem

Info

Publication number
PT669986E
PT669986E PT94901599T PT94901599T PT669986E PT 669986 E PT669986 E PT 669986E PT 94901599 T PT94901599 T PT 94901599T PT 94901599 T PT94901599 T PT 94901599T PT 669986 E PT669986 E PT 669986E
Authority
PT
Portugal
Prior art keywords
atg
expression
expression vector
intrononic
strategies
Prior art date
Application number
PT94901599T
Other languages
English (en)
Inventor
Mitchell E Reff
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/147,696 external-priority patent/US5648267A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of PT669986E publication Critical patent/PT669986E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
PT94901599T 1992-11-13 1993-11-12 Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem PT669986E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97769192A 1992-11-13 1992-11-13
US08/147,696 US5648267A (en) 1992-11-13 1993-11-03 Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same

Publications (1)

Publication Number Publication Date
PT669986E true PT669986E (pt) 2003-08-29

Family

ID=26845148

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94901599T PT669986E (pt) 1992-11-13 1993-11-12 Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem

Country Status (8)

Country Link
US (3) US5733779A (pt)
EP (1) EP0669986B1 (pt)
AT (1) ATE236987T1 (pt)
CA (1) CA2149326C (pt)
DE (2) DE669986T1 (pt)
DK (1) DK0669986T3 (pt)
ES (1) ES2088838T3 (pt)
PT (1) PT669986E (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
EP1637160A3 (en) * 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
ZA200508985B (en) * 2001-07-10 2006-07-26 Biogen Idec Inc Inhibition of apotosis process and improvement of cell performance
EA007905B1 (ru) 2001-11-16 2007-02-27 Байоджен Айдек Инк. Полицистронная экспрессия антител
WO2003072739A2 (en) * 2002-02-25 2003-09-04 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
JP4836451B2 (ja) * 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
AU2003290453A1 (en) 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
MXPA05007940A (es) * 2003-01-27 2007-06-14 Biogen Idec Inc Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
NZ607886A (en) 2003-03-19 2014-09-26 Biogen Idec Inc Nogo receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7674618B2 (en) 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
WO2005062881A2 (en) * 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
PT1776136E (pt) * 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2581422C (en) * 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
NZ553700A (en) * 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
EA200701448A1 (ru) 2005-01-05 2008-02-28 Байоджен Айдек Эмэй Инк. Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
BRPI0707276B1 (pt) 2006-01-27 2021-08-31 Biogen Ma Inc Polipeptídeo de fusão antagonista de receptor nogo
CA2646406A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-igf-ir antibodies and uses thereof
KR20090114388A (ko) 2007-01-05 2009-11-03 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
PT2740744T (pt) 2007-01-09 2018-06-06 Biogen Ma Inc Anticorpos sp35 e suas utilizações
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2114433B1 (en) 2007-02-02 2014-04-09 Biogen Idec MA Inc. Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
CN101842117A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
CA2697922A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
CN102065895A (zh) * 2008-04-11 2011-05-18 比奥根艾迪克Ma公司 抗-igf-1r抗体和其它化合物的治疗联合
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
EP2342224A2 (en) * 2008-09-25 2011-07-13 TransGenRx, Inc. Novel vectors for production of interferon
SI2370466T1 (sl) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
JP5899109B2 (ja) 2009-03-31 2016-04-06 セルトリオン・インコーポレイテッド 高発現組換え細胞系の選択方法
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
KR101800904B1 (ko) * 2009-08-06 2017-12-20 씨엠씨 아이코스 바이올로직스, 인크. 재조합 단백질 발현을 개선시키는 방법
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
JP6272299B2 (ja) 2012-04-20 2018-01-31 メルス ナムローゼ フェンノートシャップ Ｉｇ様分子を生産する方法、Ｉｇ様分子の混合物、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP2906240A2 (en) 2012-10-09 2015-08-19 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
CN109072214B (zh) 2016-02-01 2023-02-17 比奥贝拉蒂治疗公司 优化的因子viii基因
MA45668A (fr) 2016-07-13 2019-05-22 Biogen Ma Inc Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
MA46968A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
IL308416A (en) 2016-12-02 2024-01-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
CN117881696A (zh) 2021-08-23 2024-04-12 比奥维拉迪维治疗股份有限公司 具有反向末端重复序列的封闭末端dna产生
CN117836319A (zh) 2021-08-23 2024-04-05 比奥维拉迪维治疗股份有限公司 优化的因子viii基因
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same

Also Published As

Publication number Publication date
US5733779A (en) 1998-03-31
EP0669986A1 (en) 1995-09-06
ES2088838T1 (es) 1996-10-01
DE69332859D1 (de) 2003-05-15
DE69332859T2 (de) 2003-12-18
DK0669986T3 (da) 2003-07-28
CA2149326A1 (en) 1994-05-26
EP0669986B1 (en) 2003-04-09
DE669986T1 (de) 1996-10-10
ES2088838T3 (es) 2004-01-01
US6159730A (en) 2000-12-12
US6017733A (en) 2000-01-25
ATE236987T1 (de) 2003-04-15
CA2149326C (en) 2007-04-17

Similar Documents

Publication Publication Date Title
PT669986E (pt) Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem
WO1994011523A3 (en) Fully impaired consensus kozac sequences for mammalian expression
Nakashima et al. Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells
Miyata et al. Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer.
AU1824992A (en) Synthetic catalytic oligonucleotide structures containing modified nucleotides
BR9510498A (pt) Derivados de nucleosìdeos com grupos de proteção fotolábeis
ATE66693T1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
CA2169854A1 (en) Enhanced expression in plants using non-translated leader sequences
US20210163907A1 (en) Modified cas9 protein, and use thereof
Obaru et al. Cloning and sequence analysis of mRNA for mouse aspartate aminotransferase isoenzymes.
WO2002022835A3 (en) Targeted genetic manipulation using mu bacteriophage cleaved donor complex
DE59704973D1 (de) Nucleosid-derivate mit photolabilen schutzgruppen
IL128198A (en) Isolated nucleic acids and uses thereof for conferring plants with resistance to nematodes and/or aphids
DE69936919D1 (en) Fy7 polymerase
Ogawa et al. Molecular cloning, sequence analysis, and expression in Escherichia coli of the cDNA for guanidinoacetate methyltransferase from rat liver.
ATE296886T1 (de) Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung
WO1998029538A3 (de) Gen für adenylatzyklase und seine verwendung
ATE322543T1 (de) Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz
Stout et al. Antisense RNA inhibition of HPRT synthesis
Goldfarb et al. Transcription in vitro of an isolated fragment of bacteriophage T4 genome
Wynford‐Thomas et al. Suppression of transformation and immortality in human/chinese hamster fibroblast hybrids—a model for suppressor gene isolation
ATE381615T1 (de) Nukleinsäure-enzym zur spaltung von rna
Walsh et al. The role of ribosomes in stabilizing bacteriophage T4 deoxynucleotide kinase mRNA in vitro
Yong-xing et al. Isolation and Characterization of NH+ 4-Excreting Mutants of Enterobacter gergoviae
TH5997EX (th) การสร้างโปรอโปดิโปรโปรตีน a-i ของคนโดยการแสดงออกของรหัสพันธุกรรม